vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and GENCOR INDUSTRIES INC (GENC). Click either name above to swap in a different company.
GENCOR INDUSTRIES INC is the larger business by last-quarter revenue ($23.6M vs $18.7M, roughly 1.3× CytomX Therapeutics, Inc.). GENCOR INDUSTRIES INC runs the higher net margin — 14.6% vs -0.8%, a 15.4% gap on every dollar of revenue. On growth, GENCOR INDUSTRIES INC posted the faster year-over-year revenue change (-25.0% vs -25.7%). GENCOR INDUSTRIES INC produced more free cash flow last quarter ($10.1M vs $-15.8M). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -23.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.
CTMX vs GENC — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $23.6M |
| Net Profit | $-154.0K | $3.4M |
| Gross Margin | — | 28.7% |
| Operating Margin | -6.9% | 13.2% |
| Net Margin | -0.8% | 14.6% |
| Revenue YoY | -25.7% | -25.0% |
| Net Profit YoY | 97.6% | -9.8% |
| EPS (diluted) | — | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.6M | ||
| Q3 25 | — | $18.8M | ||
| Q2 25 | $18.7M | $27.0M | ||
| Q1 25 | $50.9M | $38.2M | ||
| Q4 24 | $38.1M | $31.4M | ||
| Q3 24 | $33.4M | $20.9M | ||
| Q2 24 | $25.1M | $25.6M | ||
| Q1 24 | $41.5M | $40.7M |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | $-154.0K | $3.8M | ||
| Q1 25 | $23.5M | $6.1M | ||
| Q4 24 | $18.9M | $3.8M | ||
| Q3 24 | $5.7M | $1.5M | ||
| Q2 24 | $-6.5M | $2.6M | ||
| Q1 24 | $13.8M | $6.2M |
| Q4 25 | — | 28.7% | ||
| Q3 25 | — | 24.2% | ||
| Q2 25 | — | 26.5% | ||
| Q1 25 | — | 29.7% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 25.6% | ||
| Q2 24 | — | 23.9% | ||
| Q1 24 | — | 30.3% |
| Q4 25 | — | 13.2% | ||
| Q3 25 | — | -1.2% | ||
| Q2 25 | -6.9% | 11.6% | ||
| Q1 25 | 44.4% | 17.0% | ||
| Q4 24 | 46.4% | 14.7% | ||
| Q3 24 | 12.3% | 5.9% | ||
| Q2 24 | -33.7% | 7.8% | ||
| Q1 24 | 28.1% | 17.4% |
| Q4 25 | — | 14.6% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | -0.8% | 14.2% | ||
| Q1 25 | 46.2% | 16.0% | ||
| Q4 24 | 49.6% | 12.1% | ||
| Q3 24 | 17.2% | 6.9% | ||
| Q2 24 | -26.0% | 10.0% | ||
| Q1 24 | 33.3% | 15.3% |
| Q4 25 | — | $0.23 | ||
| Q3 25 | — | $0.13 | ||
| Q2 25 | — | $0.26 | ||
| Q1 25 | — | $0.42 | ||
| Q4 24 | — | $0.26 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $147.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $215.2M |
| Total Assets | $175.1M | $228.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $147.7M | ||
| Q3 25 | — | $136.3M | ||
| Q2 25 | $49.0M | $136.0M | ||
| Q1 25 | $47.6M | $143.7M | ||
| Q4 24 | $38.1M | $130.1M | ||
| Q3 24 | $40.6M | $115.4M | ||
| Q2 24 | $43.2M | $116.6M | ||
| Q1 24 | $36.2M | $117.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $215.2M | ||
| Q3 25 | — | $211.8M | ||
| Q2 25 | $119.9M | $209.9M | ||
| Q1 25 | $25.0M | $206.1M | ||
| Q4 24 | $-456.0K | $200.0M | ||
| Q3 24 | $-23.5M | $196.1M | ||
| Q2 24 | $-31.2M | $194.7M | ||
| Q1 24 | $-31.7M | $192.1M |
| Q4 25 | — | $228.9M | ||
| Q3 25 | — | $222.6M | ||
| Q2 25 | $175.1M | $220.2M | ||
| Q1 25 | $98.5M | $223.9M | ||
| Q4 24 | $120.5M | $218.2M | ||
| Q3 24 | $139.0M | $208.1M | ||
| Q2 24 | $159.2M | $201.8M | ||
| Q1 24 | $184.7M | $206.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $11.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $10.1M |
| FCF MarginFCF / Revenue | -84.6% | 43.0% |
| Capex IntensityCapex / Revenue | 0.1% | 4.1% |
| Cash ConversionOCF / Net Profit | — | 3.23× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-3.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $-275.0K | ||
| Q2 25 | $-15.8M | $-23.9M | ||
| Q1 25 | $-21.0M | $12.4M | ||
| Q4 24 | $-19.9M | $14.8M | ||
| Q3 24 | $-20.7M | $-3.2M | ||
| Q2 24 | $-19.5M | $-1.0M | ||
| Q1 24 | $-26.0M | $11.7M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | $-15.8M | $-24.4M | ||
| Q1 25 | $-21.2M | $12.3M | ||
| Q4 24 | $-20.0M | $14.5M | ||
| Q3 24 | $-20.7M | $-3.3M | ||
| Q2 24 | $-19.6M | $-1.4M | ||
| Q1 24 | $-26.2M | $11.7M |
| Q4 25 | — | 43.0% | ||
| Q3 25 | — | -6.8% | ||
| Q2 25 | -84.6% | -90.4% | ||
| Q1 25 | -41.6% | 32.2% | ||
| Q4 24 | -52.5% | 46.1% | ||
| Q3 24 | -62.1% | -15.8% | ||
| Q2 24 | -78.2% | -5.6% | ||
| Q1 24 | -63.1% | 28.7% |
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 0.2% | 0.4% | ||
| Q4 24 | 0.2% | 1.0% | ||
| Q3 24 | 0.1% | 0.4% | ||
| Q2 24 | 0.4% | 1.5% | ||
| Q1 24 | 0.3% | 0.0% |
| Q4 25 | — | 3.23× | ||
| Q3 25 | — | -0.14× | ||
| Q2 25 | — | -6.24× | ||
| Q1 25 | -0.89× | 2.04× | ||
| Q4 24 | -1.05× | 3.88× | ||
| Q3 24 | -3.61× | -2.22× | ||
| Q2 24 | — | -0.41× | ||
| Q1 24 | -1.89× | 1.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
GENC
Segment breakdown not available.
